• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    RBC Capital Mkts resumed coverage on Amneal Pharmaceuticals with a new price target

    4/7/21 6:35:06 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email
    RBC Capital Mkts resumed coverage of Amneal Pharmaceuticals with a rating of Sector Perform and set a new price target of $5.00
    Get the next $AMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/18/25 4:11:43 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Patel Gautam sold $452,537 worth of shares (56,426 units at $8.02), decreasing direct ownership by 3% to 1,704,050 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/12/25 4:19:17 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Vice President Shah Nikita sold $372,481 worth of shares (49,140 units at $7.58), decreasing direct ownership by 11% to 388,929 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      5/19/25 4:16:23 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

      Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      6/6/25 8:33:10 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by Analyst with a new price target

      Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      2/24/25 7:02:03 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00

      9/6/24 7:29:08 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    SEC Filings

    See more
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/8/25 4:21:09 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.

      10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/7/25 4:39:31 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/2/25 6:18:24 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care